Based on the DocCheck AG stock forecast from 0 analysts, the average analyst target price for DocCheck AG is not available over the next 12 months. DocCheck AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of DocCheck AG is Slightly Bullish , which is based on 11 positive signals and 5 negative signals. At the last closing, DocCheck AG’s stock price was EUR 9.00. DocCheck AG’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -26.83% over the last year.
No recent analyst target price found for DocCheck AG
No recent average analyst rating found for DocCheck AG
Company Overview DocCheck AG
DocCheck AG offers marketing and e-commerce services for the healthcare sector in Europe. The company operates DocCheck portal for exchanging information on the Internet, as well as involved in online advertising, market research, and studies for healthcare market players. It also develops and implements communication strategies for media on healthcare and business-to-business sectors. In addition, the company invests in healthcare sectors. DocCheck AG was founded in 1990 and is based in Cologne, Germany. Address: Vogelsanger Str. 66, Cologne, Germany, 50823 Read Less
DocCheck AG offers marketing and e-commerce services for the healthcare sector in Europe. The company operates DocCheck portal for exchanging information on the Internet, as well as involved in online advertising, market research, and studies for healthcare market players. It als...Read More
Frequently Asked Questions About DocCheck AG (AJ91:XETRA) Stock
Stock Target Advisor's fundamental analysis for DocCheck AG's stock is Slightly Bullish .
AJ91:XETRA stock's dividend yield is 5.52%.
Our analysis grades AJ91:XETRA stock's dividend yield at A+. This means that AJ91:XETRA stock's dividend yield is above 100% of the stocks in the Health Information Services sector in the XETRA exchange.
Based on this AJ91:XETRA may be a good dividend stock for its sector.
Unfortunately we do not have enough data on AJ91:XETRA's stock to indicate what its average analyst target is.
AJ91:XETRA stock's Price/Earning ratio is 7.80.
Our analysis grades AJ91:XETRA stock's Price / Earning ratio at A+. This means that AJ91:XETRA stock's Price/Earning ratio is above 0% of the stocks in the Health Information Services sector in the XETRA exchange.
Based on this AJ91:XETRA may be undervalued for its sector.
The last closing price of AJ91:XETRA's stock was EUR 9.00.
The most recent market capitalization for AJ91:XETRA is EUR 0.05B.
Unfortunately we do not have enough analyst data on AJ91:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains DocCheck AG's stock.
As per our most recent records DocCheck AG has 463 Employees.
DocCheck AG's registered address is Vogelsanger Str. 66, Cologne, Germany, 50823.
You can get more information about it from DocCheck AG's website at https://www.doccheck.ag.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced on cashflow basis
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AJ91:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
